Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
This course material is a supplement to Data Analysis for Business, Economics, and Policy by Gábor Békés (CEU) and Gábor Kézdi (U. Michigan), Cambridge University Press, 2021.
Objectives To date, consistent evidence for consequences of heading in football (soccer) on the structure and function of the ...
Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...
Breaking stock news is now free. Create your account to stay informed—and explore the insights behind every move. My ...
An agentic AI-based approach to end-to-end bug resolution using both error logs and waveforms.
Findings from the phase 1/2 BRUIN study (NCT03740529) show that pirtobrutinib (Jaypirca), a Bruton tyrosine kinase inhibitor (BTKi), monotherapy offers promising clinical efficacy and a favorable ...
Conclusions Cognitive impairment is associated with increased risks of cardiovascular death and composite cardiovascular outcomes. Uncontrolled lifestyle, cardiometabolic and psychological risk ...
At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) ...
Key Takeaways. TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to ...
Scientific studies claim that modern music has become simpler than ever before, both lyrically and musically. But are they ...
The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback